ESR1 and breast carcinoma: The PEPI score was validated in the IMPACT trial86, an independent study of postmenopausal women with ER-positive, invasive, nonmetastatic, and operable or locally advanced and potentially operable breast cancer, which compared treatment with anastrozole, tamoxifen, or the combination for 3 months before surgery79,86,87.